Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
Centessa Pharmaceuticals plc - American Depositary Shares (CNTA)
Company Research
Source: GlobeNewswire
Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 interim analysis planned in 2024Orexin Agonist Program: Cleared IND and initiated Phase 1 first-in-human clinical trial of ORX750, a highly potent and selective OX2R agonist for the treatment of narcolepsy; Clinical proof-of-concept data in acutely sleep-deprived healthy volunteers planned in 2H of 2024LockBody® Technology Platform: Ongoing Phase 1/2a study of LB101 (PD-L1xCD47) for the treatment of solid tumorsCash runway, extended by recent public offering, supports clinical plans through multiple data readouts BOSTON and LONDON, May 13, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today reported financial results and business highlights for the first quarter ended March 31, 2024. “2024 is off to a stro
Show less
Read more
Impact Snapshot
Event Time:
CNTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CNTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CNTA alerts
High impacting Centessa Pharmaceuticals plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
CNTA
News
- Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)GlobeNewswire
- Centessa Pharmaceuticals plc (NASDAQ: CNTA) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $26.00 price target on the stock, up previously from $11.00.MarketBeat
- Centessa Pharmaceuticals plc (NASDAQ: CNTA) is now covered by analysts at B. Riley. They set a "buy" rating and a $33.00 price target on the stock.MarketBeat
- Centessa Pharmaceuticals plc (NASDAQ: CNTA) had its price target raised by analysts at BMO Capital Markets from $20.00 to $35.00. They now have an "outperform" rating on the stock.MarketBeat
- Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares [Yahoo! Finance]Yahoo! Finance
CNTA
Earnings
- 8/13/24 - Miss
CNTA
Sec Filings
- 10/25/24 - Form 4
- 10/25/24 - Form 144
- 10/23/24 - Form 4
- CNTA's page on the SEC website